Craig Hallum initiated coverage on Biodesix with a new price target
$BDSX
Medical Specialities
Health Care
Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | Outperform → Mkt Perform | William Blair | |
| 9/16/2024 | Sector Outperform | Scotiabank | |
| 7/26/2024 | $3.00 | Buy | Craig Hallum |
| 5/13/2024 | $2.80 | Buy | TD Cowen |
| 5/3/2024 | $3.00 | Buy | Lake Street |
| 11/17/2021 | $21.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
William Blair downgraded Biodesix from Outperform to Mkt Perform
Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform
Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00
S-8 - BIODESIX INC (0001439725) (Filer)
8-K - BIODESIX INC (0001439725) (Filer)
SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)
LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the Ame
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center. The Ver
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTLocation: Chicago, IL The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodes
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a
SC 13G/A - BIODESIX INC (0001439725) (Subject)
SC 13G - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)